SCHEDULE: L.I.A. Pure Capital Exits Clearmind Medicine Position

L.I.A. Pure Capital Ltd. has filed an amendment to its Schedule 13G, reporting a 0% beneficial ownership stake in Clearmind Medicine Inc.

Summary

• L.I.A. Pure Capital Ltd. reported that it no longer beneficially owns any shares of Clearmind Medicine Inc. common stock.
• The filing serves as an exit notification, confirming the reporting person's ownership has dropped to 0%.
• The event date triggering this filing is March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting a change in shareholder composition rather than a fundamental shift in the company's operational health.

Positives

• The filing provides transparency regarding the change in significant shareholder status.

Negatives

• The exit of a previously identified reporting person may signal a loss of institutional interest or a strategic divestment.

Risks

• Potential market volatility associated with the exit of a known shareholder.
• Reduced liquidity or institutional support for the issuer's stock.

Future Outlook

No forward-looking guidance or outlook provided in this ownership disclosure.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard regulatory disclosures for institutional investors. The exit of a reporting person is a common occurrence in the biotech sector as investment firms rebalance portfolios or conclude their positions in small-cap equities.

Comparison to Industry Standards

• The filing adheres to standard SEC requirements for reporting changes in beneficial ownership under the Securities Exchange Act of 1934.

Stakeholder Impact

• Shareholders may note the departure of this specific institutional investor.

Next Steps

• No further actions required by the reporting person regarding this issuer.

Key Dates

Keywords

Clearmind Medicine, Schedule 13G, L.I.A. Pure Capital, Divestment, Beneficial Ownership, SEC Filing